Leerink Partnrs Has Bearish Estimate for Immunic Q1 Earnings

Immunic, Inc. (NASDAQ:IMUX) – Equities research analysts at Leerink Partnrs decreased their Q1 2025 earnings estimates for Immunic in a research note issued on Tuesday, April 1st. Leerink Partnrs analyst F. Khurshid now forecasts that the company will earn ($0.25) per share for the quarter, down from their previous forecast of ($0.22). The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. Leerink Partnrs also issued estimates for Immunic’s Q2 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.71) EPS, FY2025 earnings at ($0.71) EPS, FY2026 earnings at ($0.53) EPS and FY2026 earnings at ($0.53) EPS.

A number of other equities research analysts have also recently issued reports on the company. William Blair initiated coverage on Immunic in a report on Tuesday, March 25th. They set an “outperform” rating for the company. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Immunic in a research note on Friday, February 21st. D. Boral Capital reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Immunic in a report on Tuesday, April 1st. Finally, StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $13.20.

Immunic Stock Performance

Shares of IMUX opened at $1.00 on Friday. The firm has a market cap of $89.70 million, a P/E ratio of -0.81 and a beta of 1.91. Immunic has a 52 week low of $0.92 and a 52 week high of $2.11. The firm’s 50-day simple moving average is $1.09 and its 200 day simple moving average is $1.19.

Hedge Funds Weigh In On Immunic

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IMUX. Jane Street Group LLC increased its position in shares of Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares during the period. HB Wealth Management LLC acquired a new stake in Immunic during the fourth quarter worth about $81,000. State Street Corp grew its stake in Immunic by 7.5% during the third quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after buying an additional 11,642 shares in the last quarter. Virtu Financial LLC bought a new position in Immunic in the 3rd quarter valued at about $50,000. Finally, Millennium Management LLC raised its position in shares of Immunic by 480.6% in the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock valued at $580,000 after buying an additional 479,846 shares in the last quarter. 51.82% of the stock is owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.